PL2948184T3 - ADC duokarmycyny wykazujące poprawioną aktywność przeciwnowotworową in vivo - Google Patents

ADC duokarmycyny wykazujące poprawioną aktywność przeciwnowotworową in vivo

Info

Publication number: PL2948184T3
Authority: PL; Poland
Prior art keywords: antitumor activity; vivo antitumor; showing improved; duocarmycin; duocarmycin adcs
Prior art date: 2014-01-10

Application number

PL15701106.5T

Other languages

English (en)

Inventor

Willem Dokter

Peter Johannes Goedings

Gijsbertus Franciscus Maria Verheijden

Patrick Henry Beusker

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-10

Filing date

2015-01-09

Publication date

2016-11-30

2015-01-09 Application filed filed Critical

2016-11-30 Publication of PL2948184T3 publication Critical patent/PL2948184T3/pl

Links

VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 title 1
229960005501 duocarmycin Drugs 0.000 title 1
229930184221 duocarmycin Natural products 0.000 title 1
230000005917 in vivo anti-tumor Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

PL15701106.5T 2014-01-10 2015-01-09 ADC duokarmycyny wykazujące poprawioną aktywność przeciwnowotworową in vivo PL2948184T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP14150791		2014-01-10
EP14188450		2014-10-10

Publications (1)

Publication Number	Publication Date
PL2948184T3 true PL2948184T3 (pl)	2016-11-30

Family

ID=52396655

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL15701106.5T PL2948184T3 (pl)	2014-01-10	2015-01-09	ADC duokarmycyny wykazujące poprawioną aktywność przeciwnowotworową in vivo
PL16160637T PL3069735T3 (pl)	2014-01-10	2015-01-09	ADC duokarmycyny do zastosowania w leczeniu raka pęcherza

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL16160637T PL3069735T3 (pl)	2014-01-10	2015-01-09	ADC duokarmycyny do zastosowania w leczeniu raka pęcherza

Country Status (23)

Country	Link
US (4)	US9421278B2 (pl)
EP (2)	EP3069735B1 (pl)
JP (2)	JP6342517B2 (pl)
KR (2)	KR102323302B1 (pl)
CN (1)	CN105899236B (pl)
AU (2)	AU2015205509B2 (pl)
BR (1)	BR112016015848A2 (pl)
CA (1)	CA2935433C (pl)
CL (1)	CL2016001760A1 (pl)
CY (2)	CY1117687T1 (pl)
DK (2)	DK2948184T3 (pl)
ES (2)	ES2575508T3 (pl)
HR (2)	HRP20160697T1 (pl)
HU (2)	HUE029255T2 (pl)
LT (1)	LT3069735T (pl)
MX (2)	MX368396B (pl)
NO (1)	NO3069735T3 (pl)
PL (2)	PL2948184T3 (pl)
PT (2)	PT2948184T (pl)
RU (2)	RU2769700C2 (pl)
SG (2)	SG10201911860VA (pl)
WO (1)	WO2015104385A2 (pl)
ZA (2)	ZA201604535B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9901567B2 (en)	2007-08-01	2018-02-27	Syntarga B.V.	Substituted CC-1065 analogs and their conjugates
ES2647317T3 (es)	2008-11-03	2017-12-20	Syntarga B.V.	Análogos de CC-1065 y sus conjugados
DK3108886T3 (da)	2010-04-21	2020-08-10	Syntarga Bv	Konjugater af CC-1065-analoger og bifunktionelle linkere
RU2015129800A (ru)	2012-12-21	2017-01-30	Биоэллаенс К. В.	Гидрофильные саморазрушающиеся линкеры и их конъюгаты
KR20160099725A (ko)	2014-01-10	2016-08-22	신톤 바이오파머슈티칼즈 비.브이.	자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc
EP3069735B1 (en)	2014-01-10	2018-03-14	Synthon Biopharmaceuticals B.V.	Duocarmycin adcs for use in the treatment of bladder cancer
EP3092010B1 (en)	2014-01-10	2018-07-11	Synthon Biopharmaceuticals B.V.	Method for purifying cys-linked antibody-drug conjugates
JP6517240B2 (ja)	2014-05-22	2019-05-22	シントン・バイオファーマシューティカルズ・ビー．ブイ．ＳｙｎｔｈｏｎＢｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓＢ．Ｖ．	抗体へのリンカー薬物の部位特異的コンジュゲーションおよび得られるａｄｃ
WO2015195925A1 (en)	2014-06-18	2015-12-23	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates and methods of using same
TWI695011B (zh)	2014-06-18	2020-06-01	美商梅爾莎納醫療公司	抗ｈｅｒ２表位之單株抗體及其使用之方法
KR20170020868A (ko)	2014-06-20	2017-02-24	바이오얼라이언스 씨.브이.	항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법
AU2015277100A1 (en) *	2014-06-20	2017-02-02	Abgenomics International Inc.	HER2 antibody-drug conjugates
EP3319597B1 (en)	2015-07-10	2021-02-17	Byondis B.V.	Compositions comprising antibody-duocarmycin drug conjugates
WO2017050846A1 (en) *	2015-09-22	2017-03-30	Synthon Biopharmaceuticals B.V.	Syd985 treatment of t-dm1 refractory cancer patients
CN106729743B (zh) *	2015-11-23	2021-09-21	四川科伦博泰生物医药股份有限公司	抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
WO2017091745A1 (en) *	2015-11-25	2017-06-01	Immunogen, Inc.	Pharmaceutical formulations and methods of use thereof
US10472422B2 (en)	2016-01-08	2019-11-12	Abgenomics International Inc.	Tetravalent anti-PSGL-1 antibodies and uses thereof
MX2018012433A (es) *	2016-04-15	2019-03-01	Macrogenics Inc	Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos.
GB201708909D0 (en) *	2017-06-05	2017-07-19	Orthox Ltd	Implantable tissue repair devices and methods for manufacturing the same
EP3866785A1 (en)	2018-10-15	2021-08-25	Merck Patent GmbH	Combination therapy utilizing dna alkylating agents and atr inhibitors
US20210386867A1 (en) *	2018-11-09	2021-12-16	Byondis B.V.	Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods
JP2023517477A (ja) *	2020-02-06	2023-04-26	ビョンディス・ビー．ブイ．	デュオカルマイシン誘導体含有抗体薬物複合体及びチオ硫酸類を含む組合せ

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1238907A (en)	1984-02-21	1988-07-05	Robert C. Kelly	1,2,8,8a-tetrahydrocyclopropa¬c\|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
US4771128A (en)	1986-10-10	1988-09-13	Cetus Corporation	Method of purifying toxin conjugates using hydrophobic interaction chromatography
MX9203460A (es)	1988-09-12	1992-09-01	Upjohn Co	Nuevos analogos cc-1065 que tienen dos subunidades cpi.
EP0527189A1 (en)	1990-04-25	1993-02-17	PHARMACIA & UPJOHN COMPANY	Novel cc-1065 analogs
JPH05268205A (ja)	1992-03-19	1993-10-15	Fujitsu Ltd	クロック切換え回路
ES2149768T3 (es)	1992-03-25	2000-11-16	Immunogen Inc	Conjugados de agentes enlazantes de celulas derivados de cc-1065.
JP3514490B2 (ja)	1992-08-21	2004-03-31	杏林製薬株式会社	トリフルオロメチルピロロインドールカルボン酸エステル誘導体及びその製造方法
GB9307491D0 (en)	1993-04-08	1993-06-02	Sandoz Ltd	Organic compounds
JP3565559B2 (ja)	1994-04-01	2004-09-15	協和醗酵工業株式会社	Ｄｃ−８９誘導体
US5502068A (en)	1995-01-31	1996-03-26	Synphar Laboratories, Inc.	Cyclopropylpyrroloindole-oligopeptide anticancer agents
DE19503320A1 (de)	1995-02-02	1996-08-08	Boehringer Mannheim Gmbh	Neue Benzodiazepinkonjugate
US5843937A (en)	1996-05-23	1998-12-01	Panorama Research, Inc.	DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents
DE69734722T2 (de)	1996-09-12	2006-07-20	Auckland Uniservices Ltd.	Kondensierte n-acylindole als antitumormittel
WO1998025900A1 (fr)	1996-12-13	1998-06-18	Shionogi & Co., Ltd.	Composes presentant une activite antitumorale
US20030036629A1 (en)	1997-12-12	2003-02-20	Barry Foster	Novel tgf-beta protein purification methods
EP1280771B1 (de)	2000-05-02	2004-10-13	Tietze, Lutz F., Prof. Dr.	Neue prodrugs von 6-hydroxy-2,3-dihydro-1h-indolen, 5-hydroxy-1,2-dihydro-3h-pyrrolo 3,2-e]indolen und 5-hydroxy-1,2-dihydro-3h-benzo e]indolen sowie von 6-hydroxy-1,2,3,4-tetrahydro-benzo f]chinolin-derivaten für eine selektive krebstherapie
ES2254492T3 (es)	2000-09-19	2006-06-16	Moses Lee	Composiciones y procedimientos de uso de analogos aquirales de cc-1065 y de duocarmicinas.
WO2002059122A1 (en)	2001-01-24	2002-08-01	Auckland Uniservices Limited	ANTI-CANCER 2,3-DIHYDRO-1H-PYRROLO[3,2-f]QUINOLINE COMPLEXES OF COBALT AND CHROMIUM
JP4862120B2 (ja)	2001-02-22	2012-01-25	ユニヴァーシティオブブラッドフォード	腫瘍治療のためのプロドラッグとしてのベンズ−インドールおよびベンゾ−キノリン誘導体
EP1434778A4 (en) *	2001-05-31	2005-07-13	Medarex Inc	CYTOTOXINS, PROMEDICAMENTS, BINDERS AND STABILIZERS USEFUL THEREFOR
US7514078B2 (en)	2001-06-01	2009-04-07	Cornell Research Foundation, Inc.	Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20050014700A1 (en)	2001-09-07	2005-01-20	Boger Dale L.	Cbi analogues of cc-1065 and the duocarmycins
WO2003026577A2 (en) *	2001-09-24	2003-04-03	Seattle Genetics, Inc.	P-amidobenzylethers in drug delivery agents
US6756397B2 (en)	2002-04-05	2004-06-29	Immunogen, Inc.	Prodrugs of CC-1065 analogs
US7235578B2 (en)	2002-05-17	2007-06-26	Auckland Uniservices Limited	Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3H-[ring fused indol-5-yl-(amine-derived)] compounds and analogues thereof, and to products obtained therefrom
CA2494104A1 (en) *	2002-07-31	2004-04-22	Seattle Genetics, Inc.	Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1560599A1 (en)	2002-11-14	2005-08-10	Syntarga B.V.	Prodrugs built as multiple self-elimination-release spacers
DK1592457T3 (da)	2003-01-27	2012-10-22	Endocyte Inc	Folat-vinblastin-konjugat som lægemiddel
US20070037739A1 (en)	2003-02-03	2007-02-15	Medlogics Device Corporation	Compounds useful in coating stents to prevent and treat stenosis and restenosis
ES2457538T3 (es)	2003-02-20	2014-04-28	Seattle Genetics, Inc.	Conjugados de anticuerpo anti-CD70-fármaco y su uso para el tratamiento de cánder y trastornos inmunológicos
US20050026987A1 (en)	2003-05-13	2005-02-03	The Scripps Research Institute	CBI analogues of the duocarmycins and CC-1065
WO2005032594A2 (en)	2003-10-03	2005-04-14	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Alkylators linked to polyamides as dna binding agents
ES2533695T3 (es) *	2004-03-02	2015-04-14	Seattle Genetics, Inc.	Anticuerpos cargados parcialmente y métodos para su conjugación
NZ550934A (en)	2004-05-19	2010-05-28	Medarex Inc	Chemical linkers and conjugates thereof
AU2005286607B2 (en)	2004-09-23	2011-01-27	Genentech, Inc.	Cysteine engineered antibodies and conjugates
AU2005289453A1 (en)	2004-09-27	2006-04-06	Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health	Modulating MxA expression
NZ536107A (en)	2004-10-22	2007-06-29	Auckland Uniservices Ltd	Nitrobenzindoles and their use in cancer therapy
CA2598956A1 (en)	2005-02-24	2006-08-31	Pfizer Products Inc.	Bicyclic heteroaromatic derivatives useful as anticancer agents
CA2623652C (en)	2005-09-26	2013-11-26	Medarex, Inc.	Antibody-drug conjugates and methods of use
AU2006305842B2 (en)	2005-10-26	2011-11-03	E. R. Squibb & Sons, L.L.C.	Methods and compounds for preparing CC-1065 analogs
MX2008009956A (es)	2006-02-02	2008-12-12	Syntarga Bv	Analogos de cc-1065 solubles en agua y sus conjugados.
EP1832577A1 (en)	2006-03-07	2007-09-12	Sanofi-Aventis	Improved prodrugs of CC-1065 analogs
US7695929B2 (en)	2006-11-01	2010-04-13	Ventana Medical Systems, Inc.	Haptens, hapten conjugates, compositions thereof and method for their preparation and use
AU2007333098A1 (en)	2006-12-14	2008-06-19	Medarex, Inc.	Human antibodies that bind CD70 and uses thereof
CA2678514A1 (en)	2007-02-21	2008-08-28	Medarex, Inc.	Chemical linkers with single amino acids and conjugates thereof
EP2173739B1 (en)	2007-08-01	2013-07-31	Syntarga B.V.	Substituted cc-1065 analogs and their conjugates
US9901567B2 (en)	2007-08-01	2018-02-27	Syntarga B.V.	Substituted CC-1065 analogs and their conjugates
ES2441115T3 (es)	2007-11-13	2014-01-31	The Scripps Research Institute	Derivados de CBI sujetos a activación reductora
US20090162372A1 (en)	2007-11-30	2009-06-25	Medarex, Inc.	Fibronectin ed-b antibodies, conjugates thereof, and methods of use
NZ571028A (en)	2008-09-03	2011-01-28	Auckland Uniservices Ltd	Nitrobenzindole compounds and their use in cancer treatment
WO2010033733A1 (en)	2008-09-17	2010-03-25	Endocyte, Inc.	Folate receptor binding conjugates of antifolates
EP2165710A1 (en) *	2008-09-19	2010-03-24	Institut Curie	Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
ES2647317T3 (es)	2008-11-03	2017-12-20	Syntarga B.V.	Análogos de CC-1065 y sus conjugados
WO2010070117A1 (en) *	2008-12-18	2010-06-24	Universite Libre De Bruxelles	Treatment method by the administration of anti-her2 targeted active compounds to patients with early breast cancer and her2-negative primary tumor
US8507195B2 (en) *	2009-08-20	2013-08-13	The Regents Of The University Of Colorado	MiRNAs dysregulated in triple-negative breast cancer
DK3108886T3 (da) *	2010-04-21	2020-08-10	Syntarga Bv	Konjugater af CC-1065-analoger og bifunktionelle linkere
EP2380909A1 (en) *	2010-04-26	2011-10-26	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	PTK-7 protein involved in breast cancer
EP2575880B1 (en) *	2010-05-27	2019-01-16	Genmab A/S	Monoclonal antibodies against her2 epitope
CA2832387A1 (en) *	2011-04-20	2012-10-26	Genmab A/S	Bispecifc antibodies against her2
PL2764351T3 (pl)	2011-09-29	2019-05-31	Seattle Genetics Inc	Oznaczanie nienaruszonej masy związków środków sprzężonych z białkami
US20130095172A1 (en) *	2011-10-14	2013-04-18	Genentech, Inc.	Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
US11147852B2 (en)	2011-12-23	2021-10-19	Pfizer Inc.	Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2013121175A1 (en)	2012-02-16	2013-08-22	Ucl Business Plc	Lysosome-cleavable linker
EP3069735B1 (en)	2014-01-10	2018-03-14	Synthon Biopharmaceuticals B.V.	Duocarmycin adcs for use in the treatment of bladder cancer
KR20160099725A (ko)	2014-01-10	2016-08-22	신톤 바이오파머슈티칼즈 비.브이.	자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc
EP3092010B1 (en)	2014-01-10	2018-07-11	Synthon Biopharmaceuticals B.V.	Method for purifying cys-linked antibody-drug conjugates
JP6517240B2 (ja)	2014-05-22	2019-05-22	シントン・バイオファーマシューティカルズ・ビー．ブイ．ＳｙｎｔｈｏｎＢｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓＢ．Ｖ．	抗体へのリンカー薬物の部位特異的コンジュゲーションおよび得られるａｄｃ
CN106458892B (zh)	2014-06-05	2019-10-18	斯索恩生物制药有限公司	用于制备倍癌霉素前药的改进方法
US20170320965A1 (en)	2014-09-22	2017-11-09	Synthon Biopharmaceuticals B.V.	Pan-reactive antibodies to duocarmycins
EP3319597B1 (en)	2015-07-10	2021-02-17	Byondis B.V.	Compositions comprising antibody-duocarmycin drug conjugates

2015
- 2015-01-09 EP EP16160637.1A patent/EP3069735B1/en active Active
- 2015-01-09 LT LTEP16160637.1T patent/LT3069735T/lt unknown
- 2015-01-09 CN CN201580003979.0A patent/CN105899236B/zh active Active
- 2015-01-09 RU RU2019114963A patent/RU2769700C2/ru active
- 2015-01-09 NO NO16160637A patent/NO3069735T3/no unknown
- 2015-01-09 MX MX2016009070A patent/MX368396B/es active IP Right Grant
- 2015-01-09 SG SG10201911860VA patent/SG10201911860VA/en unknown
- 2015-01-09 DK DK15701106.5T patent/DK2948184T3/en active
- 2015-01-09 KR KR1020167021563A patent/KR102323302B1/ko active IP Right Grant
- 2015-01-09 PL PL15701106.5T patent/PL2948184T3/pl unknown
- 2015-01-09 HU HUE15701106A patent/HUE029255T2/en unknown
- 2015-01-09 WO PCT/EP2015/050350 patent/WO2015104385A2/en active Application Filing
- 2015-01-09 ES ES15701106.5T patent/ES2575508T3/es active Active
- 2015-01-09 ES ES16160637.1T patent/ES2668984T3/es active Active
- 2015-01-09 DK DK16160637.1T patent/DK3069735T3/en active
- 2015-01-09 HU HUE16160637A patent/HUE037250T2/hu unknown
- 2015-01-09 BR BR112016015848A patent/BR112016015848A2/pt active Search and Examination
- 2015-01-09 AU AU2015205509A patent/AU2015205509B2/en active Active
- 2015-01-09 PL PL16160637T patent/PL3069735T3/pl unknown
- 2015-01-09 CA CA2935433A patent/CA2935433C/en active Active
- 2015-01-09 JP JP2016563256A patent/JP6342517B2/ja active Active
- 2015-01-09 PT PT157011065T patent/PT2948184T/pt unknown
- 2015-01-09 SG SG11201605602XA patent/SG11201605602XA/en unknown
- 2015-01-09 RU RU2016132759A patent/RU2689779C2/ru active
- 2015-01-09 EP EP15701106.5A patent/EP2948184B1/en active Active
- 2015-01-09 PT PT161606371T patent/PT3069735T/pt unknown
- 2015-01-09 KR KR1020217033632A patent/KR102344354B1/ko active IP Right Grant
- 2015-09-18 US US14/859,201 patent/US9421278B2/en active Active
2016
- 2016-06-17 HR HRP20160697TT patent/HRP20160697T1/hr unknown
- 2016-06-23 CY CY20161100578T patent/CY1117687T1/el unknown
- 2016-07-04 ZA ZA2016/04535A patent/ZA201604535B/en unknown
- 2016-07-08 MX MX2019011494A patent/MX2019011494A/es active IP Right Grant
- 2016-07-08 CL CL2016001760A patent/CL2016001760A1/es unknown
- 2016-07-21 US US15/216,407 patent/US20170014525A1/en not_active Abandoned
2017
- 2017-09-19 JP JP2017179104A patent/JP6430603B2/ja active Active
- 2017-10-31 US US15/798,695 patent/US10603387B2/en active Active
2018
- 2018-01-18 ZA ZA2018/00350A patent/ZA201800350B/en unknown
- 2018-05-25 CY CY20181100573T patent/CY1120288T1/el unknown
- 2018-06-05 HR HRP20180876TT patent/HRP20180876T1/hr unknown
2019
- 2019-06-28 US US16/456,177 patent/US11382982B2/en active Active
- 2019-11-13 AU AU2019264575A patent/AU2019264575B2/en active Active

Also Published As

Publication number	Publication date
AU2015205509A1 (en)	2016-07-07
LT3069735T (lt)	2018-06-11
US9421278B2 (en)	2016-08-23
ZA201604535B (en)	2018-11-28
CA2935433C (en)	2019-04-02
HUE037250T2 (hu)	2018-08-28
SG10201911860VA (en)	2020-02-27
KR20210130826A (ko)	2021-11-01
US11382982B2 (en)	2022-07-12
SG11201605602XA (en)	2016-08-30
MX2019011494A (es)	2019-11-01
MX368396B (es)	2019-10-01
DK2948184T3 (en)	2016-06-27
US20170014525A1 (en)	2017-01-19
RU2689779C2 (ru)	2019-05-29
ES2668984T3 (es)	2018-05-23
EP2948184A2 (en)	2015-12-02
HUE029255T2 (en)	2017-02-28
US10603387B2 (en)	2020-03-31
CN105899236A (zh)	2016-08-24
JP6430603B2 (ja)	2018-11-28
JP2018039809A (ja)	2018-03-15
PL3069735T3 (pl)	2018-08-31
BR112016015848A2 (pt)	2017-08-08
RU2016132759A3 (pl)	2018-08-14
ES2575508T3 (es)	2016-06-29
PT2948184T (pt)	2016-07-08
US20160008486A1 (en)	2016-01-14
DK3069735T3 (en)	2018-05-22
HRP20180876T1 (hr)	2018-07-13
AU2015205509B2 (en)	2019-08-15
AU2019264575B2 (en)	2020-10-29
AU2019264575A1 (en)	2019-12-05
WO2015104385A3 (en)	2015-08-27
CY1117687T1 (el)	2017-05-17
EP3069735A1 (en)	2016-09-21
US20190314513A1 (en)	2019-10-17
NO3069735T3 (pl)	2018-08-11
CN105899236B (zh)	2019-07-26
MX2016009070A (es)	2016-09-09
HRP20160697T1 (hr)	2016-07-15
CY1120288T1 (el)	2019-07-10
ZA201800350B (en)	2019-07-31
CL2016001760A1 (es)	2017-06-09
RU2016132759A (ru)	2018-02-16
JP2017503858A (ja)	2017-02-02
WO2015104385A2 (en)	2015-07-16
EP3069735B1 (en)	2018-03-14
EP2948184B1 (en)	2016-03-23
KR102344354B1 (ko)	2021-12-28
KR20160106693A (ko)	2016-09-12
RU2769700C2 (ru)	2022-04-05
PT3069735T (pt)	2018-05-18
KR102323302B1 (ko)	2021-11-09
CA2935433A1 (en)	2015-07-16
RU2019114963A3 (pl)	2021-09-28
US20180140711A1 (en)	2018-05-24
JP6342517B2 (ja)	2018-06-13
RU2019114963A (ru)	2019-07-17

Publication	Publication Date	Title
ZA201800350B (en)	2019-07-31	Duocarmycin adcs showing improved in vivo antitumor activity
IL243183B (en)	2018-12-31	Electrocardiogram noise reduction
PL3077268T3 (pl)	2019-06-28	Pojazd szynowy
AU361618S (en)	2015-05-06	Chair
GB2528349B (en)	2019-02-27	Chair
HK1212178A1 (en)	2016-06-10	Chair
HK1224170A1 (zh)	2017-08-18	輪椅
GB2523584B (en)	2016-01-13	Chair
GB201405500D0 (en)	2014-05-14	Rail
PL3290556T3 (pl)	2020-07-27	Struktura typu siatki
HK1212872A1 (zh)	2016-06-24	椅子
PL3290557T3 (pl)	2020-07-27	Struktura typu siatki
GB2546045B (en)	2020-07-15	Chair
GB201612258D0 (en)	2016-08-31	Rail vehicle structure
ZA201805404B (en)	2020-03-25	Anti-spin arrangement
AU354290S (en)	2014-03-13	Rail wagon
AU354270S (en)	2014-03-12	Rail wagon
AU362320S (en)	2015-06-16	Chair
AU358290S (en)	2014-10-16	Rail vehicle
AU360370S (en)	2015-02-19	Chair
ZA201408868B (en)	2015-04-29	Railway structure
AU359444S (en)	2014-12-11	Wheelchair antitip part
TWM490312U (en)	2014-11-21	Wheelchair bed structure
TWM490140U (en)	2014-11-11	Micro-connector structure
AU357867S (en)	2014-09-26	Chair